AEON CREDIT(00900.HK)首9個月收入11.9億港元 同比增加34.4%
格隆匯1月4日丨AEON CREDIT(00900.HK)公吿,2023年年度首9個月的收入為11.9億港元,同比增加34.4%。除税後溢利由2022年年度首9個月的2.5億港元增加至報吿期內的2.82億港元。每股盈利由59.77港仙增加至報吿期間的67.40港仙。截至2023年11月30日,每股資產淨值為9.4港元。
除了業務增長外,集團非常重視並把持續發展融入業務營運中。2023年9月初,集團所發行的信用卡逐步從通過全球回收標準的更可持續塑料rPVC取代傳統的PVC塑料。此舉進一步強化了集團可持續發展承諾,並提供可持續性的卡類產品選擇給具環保意識的消費者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.